We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Fundamental aspects
-
1. Inflammation and tissue homeostasis
- Prof. Herman Waldmann
-
2. Introduction to the immune system
- Prof. Herman Waldmann
-
3. Hematopoiesis: the making of an immune system
- Prof. Paul J. Fairchild
-
4. Inflammation: purposes, mechanisms and development
- Prof. Pietro Ghezzi
-
5. Phagocytosis
- Dr. Eileen Uribe-Querol
-
6. Regulated cell death mechanisms and their crosstalk with the immune system 1
- Dr. Luis Alberto Baena-Lopez
-
7. Regulated cell death mechanisms and their crosstalk with the immune system 2
- Dr. Luis Alberto Baena-Lopez
- Innate immunity
-
11. Cells of the innate immune system
- Prof. Kevin Maloy
-
12. Microbial recognition and the immune response
- Dr. Dana Philpott
-
13. Toll-like receptor signalling during infection and inflammation
- Prof. Luke O'Neill
- Intercellular mediators
-
14. Chemokines
- Dr. James E. Pease
-
15. Cytokines
- Prof. Iain McInnes
-
16. IL-1 family cytokines as the canonical DAMPs of the immune system
- Prof. Seamus Martin
-
17. Glycans at the frontiers of inflammation, autoimmunity and cancer
- Prof. Salomé S. Pinho
-
18. Glycoimmunology
- Prof. Paula Videira
- Adaptive immunity B cells
-
21. Antigen recognition in the immune system
- Prof. Herman Waldmann
-
22. B cell biology
- Prof. Richard Cornall
-
23. Antibody structure and function: antibody structure
- Dr. Mike Clark
-
24. Antibody structure and function: antibody function
- Dr. Mike Clark
-
25. Antibody genes and diversity
- Dr. Mike Clark
-
26. In vivo antibody discovery and hybridoma technology
- Prof. Dr. Katja Hanack
-
27. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
29. The immunobiology of Fc receptors
- Prof. Mark Cragg
-
30. Immunoreceptors
- Prof. Anton van der Merwe
-
31. Affinity, avidity and kinetics in immune recognition
- Prof. Anton van der Merwe
- Adaptive immunity T cells
-
32. The thymus and T cell development: a primer
- Prof. Georg Holländer
-
33. Lineage decisions in the thymus: T cell lineage commitment
- Prof. Bruno Silva-Santos
-
34. Lineage decisions in the thymus: αβ and γδ T cell lineages
- Prof. Bruno Silva-Santos
-
35. CD4 T cell subsets
- Dr. Brigitta Stockinger
-
36. Cytotoxic T lymphocytes
- Prof. Gillian Griffiths
-
37. Gamma delta T-cells
- Prof. Bruno Silva-Santos
-
38. Tfh and Tfr cells
- Prof. Luis Graca
-
39. Tissue resident memory T cells (TRM)
- Dr. Marc Veldhoen
-
40. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
- The importance of the MHC in immunity
-
41. The MHC and MHC molecules 1
- Prof. Jim Kaufman
-
42. The MHC and MHC molecules 2
- Prof. Jim Kaufman
-
43. Natural killer cells
- Dr. Philippa Kennedy
-
45. NK cells in viral immunity
- Prof. Lewis Lanier
- Lymphocyte activation
-
46. Signal transduction by leukocyte receptors
- Dr. Omer Dushek
-
47. Immunological memory 1
- Prof. David Gray
-
48. Immunological memory 2
- Prof. David Gray
-
49. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
- Major cellular partners in immunity
-
50. The mononuclear phagocyte system - tissue resident macrophages: distribution and functions
- Prof. Emeritus Siamon Gordon
-
51. The mononuclear phagocyte system: tissue resident macrophages - activation and regulation
- Prof. Emeritus Siamon Gordon
-
52. Dendritic cells: professional antigen presenting cells
- Prof. Paul J. Fairchild
-
53. Mucosal immunology
- Prof. Daniel Mucida
- Immunological tolerance and regulation
-
54. Self-tolerance
- Prof. Herman Waldmann
-
55. Tolerance and autoimmunity
- Prof. Emerita Anne Cooke
-
56. The balance between intestinal immune homeostasis and inflammation
- Prof. Dr. Janneke Samsom
- Translational immunology - immune deficiency
-
57. Primary immunodeficiency disorders
- Dr. Smita Y. Patel
-
58. Changes in innate and adaptive immunity during human ageing 1
- Dr. Roel De Maeyer
-
59. Changes in innate and adaptive immunity during human ageing 2
- Dr. Roel De Maeyer
-
60. The aging immune system
- Prof. Ana Caetano
- Translational immunology - protection against pathogenic microbes
-
61. Immune responses to viruses
- Prof. Paul Klenerman
-
62. HIV and the immune system
- Prof. Quentin Sattentau
-
63. COVID-19: the anti-viral immune response
- Prof. Danny Altmann
-
64. Bacterial immune evasion
- Prof. Christoph Tang
-
65. The immunology underlying tuberculosis
- Prof. Thomas R. Hawn
-
66. Innate immunity to fungi
- Prof. Gordon D. Brown
-
67. Parasite immunity: introduction and Plasmodium
- Dr. Catarina Gadelha
-
68. Parasite immunity: Leishmania and Schistosoma
- Dr. Catarina Gadelha
-
69. Vaccination
- Dr. Anita Milicic
-
70. The history of vaccines 1
- Prof. Emeritus Anthony R. Rees
-
71. The history of vaccines 2
- Prof. Emeritus Anthony R. Rees
-
72. The history of vaccines 3
- Prof. Emeritus Anthony R. Rees
-
73. The science of vaccine adjuvants
- Dr. Derek O'Hagan
- Translational immunology - hypersensitivity, autoimmune disease and their management
-
74. Hypersensitivity diseases: type 1 hypersensitivity
- Prof. Herman Waldmann
-
75. Innate lymphoid cells in allergy
- Prof. Emeritus Shigeo Koyasu
-
76. Hypersensitivity diseases: type II-IV hypersensitivity
- Prof. Sara Marshall
-
77. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
78. Interleukin-17: from clone to clinic
- Prof. Leonie Taams
-
79. Autoimmunity and type 1 diabetes
- Prof. Emerita Anne Cooke
-
80. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
81. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
82. Monoclonal antibodies in haemato-oncology
- Prof. Mark Cragg
-
83. Therapeutic antibodies
- Dr. Geoffrey Hale
-
84. Neuroimmunometabolism
- Prof. Ana Domingos
-
85. The immunology of multiple sclerosis
- Dr. Joanne Jones
-
86. Understanding myasthenia gravis and advances in its management
- Prof. Henry J. Kaminski
-
87. The immunology underlying rheumatic diseases
- Dr. Hussein Al-Mossawi
-
89. Complement and lupus
- Prof. Marina Botto
-
90. Immune mechanisms in liver diseases
- Prof. Paul Klenerman
- Translational immunology - transplantation immunology
-
91. Principles of transplantation: overview of the immune response
- Prof. Emerita Kathryn Wood
-
92. Factors influencing outcomes in clinical transplantation 1
- Prof. Emerita Kathryn Wood
-
93. Factors influencing outcomes in clinical transplantation 2
- Prof. Emerita Kathryn Wood
- Translational immunology - cancer immunology
-
94. Cancer immunology
- Prof. Tim Elliott
-
95. Cancer immunotherapy
- Prof. Tim Elliott
-
96. Myeloid-derived suppressor cells in cancer
- Prof. Dmitry Gabrilovich
-
97. IL-2 in the immunotherapy of autoimmunity and cancer
- Prof. Thomas Malek
-
98. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
Printable Handouts
Navigable Slide Index
- Introduction
- Transplantation facts: USA, UK and Eurotransplant
- Immunosuppressive drugs (1)
- Immunosuppressive drugs (2)
- Long-term graft survival
- Half-lives for adult kidney transplant recipients (1)
- The immune responses to an allograft
- Rejection
- Immunosuppressive drugs (3)
- Nomenclature of mAbs in clinical use
- Sites at which immunosuppressive agents might act to inhibit rejection (1)
- Immunosuppressive agents targeting signal (1)
- Calcineurin inhibitors block IL-2 transcription and inhibit proliferation
- Sites at which immunosuppressive agents might act to inhibit rejection (2)
- Immunosuppressive agents targeting signal (2)
- Immunosuppressive agents targeting the cell cycle
- Sites at which immunosuppressive agents might act to inhibit rejection (3)
- Immunosuppressive agents targeting B cells and complement
- Incidence of first acute rejection
- Half-lives for adult kidney transplant recipients (2)
- Transplantation facts: USA
- Alloantibodies can trigger rejection
- Antibody-mediated rejection (AMR) (1)
- Hyperacute rejection: the presence of preformed anti-donor antibodies
- Determination of a patient’s antibody profile
- Technology available
- HLA antibody specificity determination using single antigen bead technology
- Defining a patient’s antibody profile
- Antibody-mediated rejection (AMR) (2)
- B cells can play multiple roles in graft rejection
- HLA and non-HLA donor specific antibodies can trigger rejection
- Graft survival of DSA negative vs DSA positive kidney transplants
- Antibody-mediated rejection (AMR) (3)
- End of part 1
Topics Covered
- Clinical transplantation
- Immunosuppressive drugs
- Long-term graft survival
- Immune responses to transplants
- Rejection
- Alloantibodies
- Antibody-mediated rejection (AMR)
- Hyperacute rejection
- Technology available for detecting and specifying HLA and non-HLA antibodies
- B cells and transplant rejection
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Wood, K. (2021, September 29). Factors influencing outcomes in clinical transplantation 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 2, 2024, from https://hstalks.com/bs/4748/.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Emerita Kathryn Wood has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Factors influencing outcomes in clinical transplantation 1
Published on September 29, 2021
47 min
A selection of talks on Immunology & Inflammation
Transcript
Please wait while the transcript is being prepared...
0:00
A very warm welcome to this lecture on transplantation,
where in this session we're going to look at the factors influencing outcomes in clinical transplantation.
My name is Kathryn Wood, I'm Professor Emerita of Immunology at the University of Oxford,
where I work with my team in the Nuffield Department of Surgical Sciences
alongside the clinical transplant team.
In the first part of this talk I'm going to cover aspects that affect outcomes in clinical transplantation.
0:29
Transplantation is a very important part of modern medicine, and with organ failure or organ diseases
becoming more prevalent, particularly (for example) diabetes and kidney failure,
the number of patients who are waiting for a transplant is ever-increasing.
I've retrieved some of the facts from the organ sharing and database systems available in the US,
the UK, and Eurotransplant, to illustrate these facts.
In the United States, a patient is added to the waiting list for a transplant every ten minutes.
When I did the survey most recently, there were 114,000-plus patients waiting for a transplant,
that is patients who are well enough to be listed as eligible for a transplant, if an organ donor becomes available.
Also, obviously because there is an organ shortage - in other words, insufficient donors for every person
who would benefit, potentially, from receiving an organ transplant -
on average, 20 people die every day while waiting for a transplant.
Largely, these are people who need a heart transplant or a liver transplant,
but even kidney transplant patients can become so unwell they are longer be eligible for a transplant,
so a large number of people are dying every day while on the transplant waiting lists.
Having said that, a more positive outlook is that there are a large number of transplants
being performed in most countries around the world now,
very successfully with good outcomes, as I'll illustrate as we go through this talk.
These are the latest data available from the various databases,
in fact, each of the countries updates their information annually, and you can
find this on a number of different websites available to the general public.
In 2020, in the United States, there were over 39,000 transplants performed.
In the UK, in 2020, there were 4,761 transplants performed,
and in Eurotransplant, which is an organisation that covers a number of different countries in Europe,
there were 6,356 transplants performed.
A large number of people are being helped because of the gift of life being provided by individuals
who wish to donate their organs for transplantation after their own death, and this is
a very important element of treating patients with end-stage organ failure.